Prelude Therapeutics Inc.Wilmington, DE, United States
I am Director of Translational Research at Prelude Therapeutics, Inc.
0080: Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
Sunday, November 12, 20239:00 AM – 11:00 AM PT
Disclosure information not submitted.